Overview

Safety and Comfort of AL-4943A Ophthalmic Solution

Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the ocular comfort and safety of olopatadine hydrochloride opthalmic solution. 0.7%.
Phase:
Phase 1
Details
Lead Sponsor:
Alcon Research
Treatments:
Ketotifen
Olopatadine Hydrochloride
Ophthalmic Solutions
Pharmaceutical Solutions